Gubra Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Gubra wird ein jährliches Gewinn- und Umsatzwachstum von 108.4% bzw. 51.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 108.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.6% betragen.
Wichtige Informationen
108.4%
Wachstumsrate der Gewinne
108.33%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 21.3% |
| Wachstumsrate der Einnahmen | 51.2% |
| Zukünftige Eigenkapitalrendite | 10.56% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 20 Aug 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Earnings Beat: Gubra A/S (CPH:GUBRA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Gubra A/S ( CPH:GUBRA ) missed earnings with its latest half-yearly results, disappointing overly-optimistic...
GUBRA: Early Obesity Trial Progress Will Support Long Term Upside
Analysts have lifted their fair value estimate for Gubra from DKK 451.50 to DKK 501.00. They cite updated assumptions for revenue growth, profit margin and future P/E as key drivers of the higher price target.
Obesity Drug Partnerships And CRO Demand Will Support Steady Long-Term Prospects
Catalysts About Gubra Gubra is a peptide focused biotech and CRO company that develops obesity and metabolic drug candidates while providing preclinical research services to pharmaceutical and biotech clients. What are the underlying business or industry changes driving this perspective?GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside
Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.GUBRA: Obesity Pipeline Progress And Phase 2 Milestones Will Drive Long Term Upside
Analysts have trimmed their price target for Gubra from DKK 469.50 to DKK 451.50, citing slightly softer revenue growth expectations and a modestly lower projected profit margin. This is partly offset by a small reduction in the discount rate and a marginally lower future P/E assumption.Analysts' Revenue Estimates For Gubra A/S (CPH:GUBRA) Are Surging Higher
Gubra A/S ( CPH:GUBRA ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...GUBRA: Obesity Trial Pipeline Will Drive Long Term Upside
Analysts have kept their DKK 469.50 price target on Gubra unchanged, citing only minor tweaks to inputs such as discount rate, revenue growth, profit margin and forward P/E assumptions, rather than any shift in their overall view. What's in the News Gubra has called its annual general meeting for March 26, 2026, with the board proposing to renew and extend its authorization to issue warrants, including an increase of 120,277 warrants and an extension of the authorization period to March 26, 2031 (Key Developments).GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).GUBRA: Obesity Trial And Ventures Expansion Will Drive Future Upside Potential
Analysts have kept their DKK price target for Gubra unchanged at DKK469.50, citing essentially stable assumptions on discount rate, revenue trajectory, profit margin and forward P/E as reasons to maintain their prior valuation view. What's in the News Clinical trial application submitted in Germany for GUB-UCN2, a first in human Phase 1/2a study targeting high quality weight loss, with about 188 participants across multiple indications and patient groups, including combination use with incretin based therapy for obesity (Product Related Announcement).GUBRA: Future Obesity Trial And Ventures Platform Will Drive Upside Potential
Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing model adjustments that reflect a slightly higher discount rate, softer revenue expectations, a lower projected profit margin and a higher future P/E multiple. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study aimed at high quality weight loss, with a design that looks at safety, tolerability, pharmacokinetics, preliminary efficacy, muscle volume and muscle function in about 188 participants, including both healthy volunteers and people living with obesity, as a standalone therapy and in combination with incretin based treatment.GUBRA: Future Pipeline Milestones And Royalties Will Drive Upside Potential
Analysts have reduced their price target for Gubra from DKK 502.50 to DKK 469.50, reflecting updated views on discount rates, revenue contraction, profit margins and a significantly lower future P/E multiple. What's in the News Gubra plans an Analyst and Investor Day event, giving the market a closer look at its business model, pipeline and long term priorities (Key Developments).AbbVie Agreement And Clinical Trials Will Unlock New Avenues
The significant downward revision in Gubra’s consensus price target reflects lowered expectations for future growth and earnings, as evidenced by reduced forecasts for both revenue growth and the future P/E multiple, resulting in a new fair value estimate of DKK540. What's in the News Extraordinary cash dividend of DKK 1 billion (DKK 61.2 per share) approved at EGM.Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Gubra A/S ( CPH:GUBRA ) shares have had a really impressive month, gaining 35% after a shaky period beforehand...AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Gubra A/S ( CPH:GUBRA ) shareholders that were waiting for something to happen have been dealt a blow with a 26% share...We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Gubra A/S ( CPH:GUBRA ) shareholders would be excited to see that the share price has had a great month, posting a 25...Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Despite an already strong run, Gubra A/S ( CPH:GUBRA ) shares have been powering on, with a gain of 60% in the last...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,314 | 574 | 321 | 367 | 3 |
| 12/31/2027 | 519 | -57 | 32 | 54 | 3 |
| 12/31/2026 | 683 | 122 | 123 | 158 | 2 |
| 6/30/2026 | 271 | -182 | -797 | -759 | N/A |
| 3/31/2026 | 1,454 | 754 | 448 | 477 | N/A |
| 12/31/2025 | 2,637 | 1,691 | 1,693 | 1,712 | N/A |
| 9/30/2025 | 2,637 | 1,719 | 1,986 | 2,007 | N/A |
| 6/30/2025 | 2,637 | 1,746 | 2,278 | 2,302 | N/A |
| 3/31/2025 | 1,451 | 855 | 1,126 | 1,153 | N/A |
| 12/31/2024 | 266 | -36 | -27 | 5 | N/A |
| 9/30/2024 | 245 | -42 | -39 | -10 | N/A |
| 6/30/2024 | 224 | -47 | -50 | -25 | N/A |
| 3/31/2024 | 214 | -46 | -55 | -37 | N/A |
| 12/31/2023 | 205 | -45 | -61 | -49 | N/A |
| 9/30/2023 | 204 | -26 | -58 | -47 | N/A |
| 6/30/2023 | 204 | -7 | -56 | -45 | N/A |
| 3/31/2023 | 201 | -1 | -23 | -10 | N/A |
| 12/31/2022 | 199 | 4 | 10 | 24 | N/A |
| 12/31/2021 | 255 | 68 | 61 | 89 | N/A |
| 12/31/2020 | 172 | 13 | 26 | 33 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: GUBRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.1%).
Ertrag vs. Markt: GUBRA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: GUBRA wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: GUBRADie Einnahmen des Unternehmens (51.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Danish (4% pro Jahr).
Hohe Wachstumseinnahmen: GUBRADie Einnahmen des Unternehmens (51.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: GUBRADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.6%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/24 13:34 |
| Aktienkurs zum Tagesende | 2026/08/21 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Gubra A/S wird von 3 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |